Robert Pozen - Medtronic PLC Independent Director
| MDT Stock | USD 79.19 0.11 0.14% |
Director
Mr. Robert Charles Pozen is an Independent Director of the Company. Mr. Pozen was Chairman of MFS Investment Management and a director of MFS Mutual Funds from 2004 to 2010, and Chairman Emeritus of MFS Investment Management from 2010 to 2011. He previously was Secretary of Economic Affairs for the Commonwealth of Massachusetts in 2003 and the John Olin Visiting Professor at Harvard Law School from 2002 to 2003. He also was Vice Chairman of Fidelity Investments from 2000 to 2001 and President of Fidelity Management Research from 1997 to 2001. From 2007 to 2008, he was the chairman of the SEC Advisory Committee on Improvements to Financial Reporting and from January 2008 through June 2015, he was a senior lecturer at Harvard Business School since 2004.
| Age | 71 |
| Tenure | 20 years |
| Address | 20 On Hatch, Dublin, Ireland, 2 |
| Phone | 353 1 438 1700 |
| Web | https://www.medtronic.com |
Medtronic PLC Management Efficiency
The company has Return on Asset of 0.0423 % which means that on every $100 spent on assets, it made $0.0423 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0817 %, implying that it generated $0.0817 on every 100 dollars invested. Medtronic PLC's management efficiency ratios could be used to measure how well Medtronic PLC manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.18 in 2024, whereas Return On Capital Employed is likely to drop 0.05 in 2024. Total Current Liabilities is likely to gain to about 10.9 B in 2024. Liabilities And Stockholders Equity is likely to gain to about 109.8 B in 2024Similar Executives
| Showing other executives | DIRECTOR Age | ||
| George Llado | Charles River Laboratories | 55 | |
| Joshua Bekenstein | Waters | 56 | |
| Scott Sperling | Thermo Fisher Scientific | 63 | |
| Elisha Finney | Mettler Toledo International | 59 | |
| Dion Weisler | Thermo Fisher Scientific | 53 | |
| Frances Arnold | Illumina | 61 | |
| Michael Kelly | Mettler Toledo International | 64 | |
| Roy Whitfield | Illumina | 63 | |
| Michael Berendt | Waters | 71 | |
| George Massaro | Charles River Laboratories | 73 | |
| Tyler Jacks | Thermo Fisher Scientific | 59 | |
| Edward Conard | Waters | 63 | |
| Lars Sorensen | Thermo Fisher Scientific | 67 | |
| Christopher Kuebler | Waters | 66 | |
| Deborah Kochevar | Charles River Laboratories | 64 | |
| JeanPaul Mangeolle | Charles River Laboratories | 57 | |
| Bryan Brokmeier | Waters | N/A | |
| Rebecca Chambers | Illumina | N/A | |
| Heidi Fields | Agilent Technologies | 60 | |
| Sperling Sperling | Thermo Fisher Scientific | 58 | |
| Hans Maerki | Mettler Toledo International | 71 | |
Management Performance
| Return On Equity | 0.0817 | ||||
| Return On Asset | 0.0423 |
Medtronic PLC Leadership Team
Elected by the shareholders, the Medtronic PLC's board of directors comprises two types of representatives: Medtronic PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medtronic. The board's role is to monitor Medtronic PLC's management team and ensure that shareholders' interests are well served. Medtronic PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medtronic PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brett Wall, Executive Vice President and President Restorative Therapies Group | ||
| Jennifer Kirk, Chief Accounting Officer, Global Controller | ||
| Bradley Lerman, Senior Vice President General Counsel, Corporate secretary | ||
| Scott Donnelly, Lead Independent Director | ||
| Kenneth Washington, Senior Officer | ||
| Richard Anderson, Lead Independent Director | ||
| Ryan Weispfenning, Vice President - Investor Relations | ||
| Mark Ploof, Senior Services | ||
| Sean Lennon, Chief Officer | ||
| Hooman Hakami, Executive Vice President and Group President of the Medtronic Diabetes Group | ||
| Elizabeth Nabel, Independent Director | ||
| Richard Kuntz, Senior Vice President and Chief Scientific, Clinical and Regulatory Officer | ||
| James Lenehan, Independent Director | ||
| John Liddicoat, Executive Vice President and President Americas Region | ||
| Shirley Jackson, Independent Director | ||
| Robert White, Executive Vice President and President of Medtronic’s Minimally Invasive Therapies Group | ||
| Preetha Reddy, Independent Director | ||
| Kevin Lofton, Independent Director | ||
| Craig Arnold, Independent Director | ||
| Robert Pozen, Independent Director | ||
| Kendall Powell, Lead Independent Director | ||
| Bryan Hanson, Executive VP and Group President of Minimally Invasive Therapies Group | ||
| Sally Saba, Chief Inclusion and Diversity Officer | ||
| Denise OLeary, Independent Director | ||
| Omar Ishrak, Chairman of the Board, Chief Executive Officer | ||
| Brad Lerman, Senior Vice President General Counsel, Corporate secretary | ||
| Ivan Fong, General VP | ||
| Sean Salmon, Executive Vice President and President, Diabetes Operating Unit, President, Cardiovascular Portfolio | ||
| Gary Ellis, CFO and Executive VP | ||
| Carol Surface, Chief Human Resource Officer, Senior Vice President | ||
| Karen Parkhill, Chief Financial Officer, Executive Vice President | ||
| Geoff Martha, Executive Vice President and President - Restorative Therapies Group | ||
| Michael Leavitt, Independent Director | ||
| Geoffrey Martha, Executive Vice President and President - Restorative Therapies Group | ||
| Randall Hogan, Independent Director | ||
| Andrea Goldsmith, Independent Director | ||
| Robert Hoedt, Executive Vice President and President - EMEA Region | ||
| MSc MD, Medical Scientific | ||
| Michael Coyle, Executive Vice President, Group President - Cardiac and Vascular Group |
Medtronic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medtronic PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0817 | ||||
| Return On Asset | 0.0423 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.19 % | ||||
| Current Valuation | 122.22 B | ||||
| Shares Outstanding | 1.33 B | ||||
| Shares Owned By Insiders | 0.10 % | ||||
| Shares Owned By Institutions | 85.20 % | ||||
| Number Of Shares Shorted | 12.43 M | ||||
| Price To Earning | 20.44 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medtronic PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Medtronic Stock please use our How to Invest in Medtronic PLC guide.Note that the Medtronic PLC information on this page should be used as a complementary analysis to other Medtronic PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for Medtronic Stock analysis
When running Medtronic PLC's price analysis, check to measure Medtronic PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medtronic PLC is operating at the current time. Most of Medtronic PLC's value examination focuses on studying past and present price action to predict the probability of Medtronic PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medtronic PLC's price. Additionally, you may evaluate how the addition of Medtronic PLC to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |
Is Medtronic PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Medtronic PLC. If investors know Medtronic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Medtronic PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.078 | Dividend Share 2.75 | Earnings Share 3.15 | Revenue Per Share 24.298 | Quarterly Revenue Growth 0.047 |
The market value of Medtronic PLC is measured differently than its book value, which is the value of Medtronic that is recorded on the company's balance sheet. Investors also form their own opinion of Medtronic PLC's value that differs from its market value or its book value, called intrinsic value, which is Medtronic PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Medtronic PLC's market value can be influenced by many factors that don't directly affect Medtronic PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Medtronic PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if Medtronic PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medtronic PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.